Here are the Form 4 insider transactions from Fennec Pharmaceuticals Inc. (FENC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FENC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FENC filings page.
Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired additional common shares through a derivative exercise/conversion. On April 30, 2026, 155 common shares were released from restriction from shares awarded on March 28, 2025, increasing her directly held stake.
Following this release, Cioffi directly owns 24,020 common shares. The transaction reflects routine equity-based compensation vesting rather than an open-market purchase, as the reported price per share was $0.0000.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported acquiring 1,159 common shares through the exercise or conversion of a derivative award. A footnote explains these shares were released from restriction from shares awarded on 3/28/2025.
After this transaction, Hackman directly holds 61,666 common shares. The filing reflects a routine compensation-related release of previously granted equity rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade acquired 1,703 common shares on April 30, 2026 through an exercise or conversion of a derivative security reported at $0.00 per share.
After this transaction, Andrade directly owns 287,566 common shares. A footnote explains these shares were released from restriction from awards originally granted on May 16, 2024 and March 28, 2025.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on April 30, 2026 through the release of restricted shares that were originally awarded on March 28, 2025. After this compensation-related share release, he directly owns a total of 20,847 Common Shares.
Cioffi Christiana Marie reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported compensation-related equity awards. She received incentive stock options for 120,000 common shares at $5.77 per share, expiring on March 31, 2036, under the 2020 Equity Incentive Plan. Performance share units and previously awarded restricted shares also vested, increasing her directly held common shares to 23,865 as of March 28, 2026.
FENNEC PHARMACEUTICALS INC. reported that Chief Executive Officer Jeffrey S. Hackman received an incentive stock option grant to purchase 200,000 common shares at $5.77 per share, expiring on March 31, 2036, under the company’s 2020 Equity Incentive Plan.
On March 31, 2026, one-third of these options become exercisable, with additional portions vesting monthly so that all 200,000 options are vested by March 31, 2029. Hackman also acquired additional common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025.
FENNEC PHARMACEUTICALS director Rosty Raykov exercised stock options and sold shares in a largely pre-planned, tax-related transaction. On April 1, 2026, he exercised 15,598 stock options at $2.45 per share, acquiring the same number of common shares under a Rule 10b5-1 trading plan adopted on September 19, 2025. On the same date, he sold 10,946 common shares at $6.31 per share to satisfy tax obligations related to the option exercise, also under that plan. A day earlier, on March 31, 2026, he received 5,208 common shares as a grant released from prior restricted awards. After these trades, he directly owned 113,856 common shares, indicating he retained most of the exercised shares.
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported equity compensation activity. On March 31, 2026, he received incentive stock options for 120,000 common shares at $5.77 per share, expiring March 31, 2036, under the 2020 Equity Incentive Plan.
One-third of these options vest on March 31, 2027, with additional vesting monthly until fully vested by March 31, 2029. The filing also shows settlement of performance share units and release of restricted shares, bringing direct holdings to 20,679 common shares. All transactions reflect awards and vesting rather than open‑market trading.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L Evans received an incentive stock option grant covering 120,000 common shares at an exercise price of $5.77 per share. The options were granted under the 2020 Equity Incentive Plan and vest over time, with one-third exercisable as of March 31, 2027 and the remainder vesting monthly so that all are vested by March 31, 2029.
On the same date, Evans also acquired common shares through the settlement of performance share units that vested on March 31, 2026 and through the release of previously restricted shares awarded on March 28, 2025. Following these equity awards and releases, Evans directly holds 20,679 common shares and 270,000 stock options, reflecting routine compensation-related transactions rather than open-market buying or selling.
Andrade Robert reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. reported insider equity awards for Chief Financial Officer Robert Andrade. On March 31, 2026, he received incentive stock options to purchase 120,000 common shares at $5.77 per share under the 2020 Equity Incentive Plan, vesting monthly from March 31, 2027 until March 31, 2029.
On the same date, 14,724 common shares were issued from settlement of PSUs that vested, and 2,213 common shares were released from restriction from prior awards. On March 28, 2026, 12,270 additional common shares were released from restriction from a 2025 award. Following these transactions, he directly holds 273,593 common shares and 921,045 stock options.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade exercised stock options to acquire 13,072 common shares at an exercise price of $5.10 per share. This option exercise converts a derivative award into shares without any open-market buying or selling.
Following the transaction, Andrade directly holds 256,656 common shares. The filing reflects a compensation-related option exercise rather than a discretionary purchase or sale in the market.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi exercised stock options to acquire 4,700 common shares at an exercise price of $4.23 per share. Following the transaction, she holds 145,300 common shares directly, indicating an exercise-and-hold transaction with no reported share sales.
Fennec Pharmaceuticals Inc. reported that its Chief Financial Officer, Robert Andrade, acquired 1,191 common shares as a grant or award at a price of $0.00 per share. A footnote explains these shares were released from restrictions on awards originally granted on 3/31/2023 and 5/16/2024. Following this transaction, Andrade directly owns 243,584 common shares.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported multiple equity transactions. On March 2, 2026, he exercised 15,598 stock options at $2.45 per share, receiving the same number of common shares under a 10b5-1 plan adopted on September 19, 2025. He then sold 10,079 common shares at $8.36 per share to cover tax obligations linked to the option exercise. On February 28, 2026, he also acquired 5,208 common shares at no cost as previously awarded shares were released from restrictions. After these transactions, his direct common share holdings were 103,996 shares.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman acquired common shares through an equity award vesting. On settlement of performance share units that vested on February 18, 2026, he received 13,710 common shares at no stated exercise price. Following this non-cash derivative exercise, his direct ownership increased to 28,710 common shares.
FENNEC PHARMACEUTICALS INC. chief financial officer Robert Andrade reported equity award activity involving both stock options and performance share units. On February 18, 2026, he exercised stock options for 2,450 shares at $4.08 per share, resulting in 215,108 common shares held directly after that transaction. He also acquired 27,285 additional common shares at no exercise price through the settlement of PSUs that vested on the same date, bringing his directly held common shares to 242,393. Following these transactions, his directly held stock options totaled 814,117.
Fennec Pharmaceuticals director Rosty Raykov reported insider transactions involving stock options and common shares. On February 2, 2026, he exercised 15,598 stock options at an exercise price of $2.45 per option under a Rule 10b5-1 trading plan adopted on September 19, 2025, receiving the same number of common shares.
On the same date, he sold 10,349 common shares at $7.76 per share to satisfy tax obligations related to the option exercise. After these transactions, he directly owned 98,477 common shares and 1,602,988 stock options in Fennec Pharmaceuticals.
Fennec Pharmaceuticals director Rosty Raykov reported a routine equity change as 5,208 common shares were acquired on January 31, 2026 at a price of $0 per share. These shares were released from restrictions tied to awards originally granted on March 31, 2023 and May 16, 2024.
Following this release of previously awarded stock, Raykov directly beneficially owns 93,228 common shares of Fennec Pharmaceuticals. The filing reflects a non-cash change in ownership from restricted to freely releasable shares rather than an open-market purchase or sale.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported an equity change in the company’s common shares. On January 31, 2026, he acquired 1,558 common shares at a price of $0 per share through the release of restrictions on previously awarded shares.
These shares were released from restriction from awards originally granted on March 31, 2023 and May 16, 2024. Following this vesting event, Andrade directly holds a total of 212,658 common shares of Fennec Pharmaceuticals.
Fennec Pharmaceuticals Inc. chief financial officer exercises stock options for 10,000 shares. On January 23, 2026, CFO Robert Andrade exercised stock options with a strike price of $2.45 per share, acquiring 10,000 common shares of Fennec Pharmaceuticals Inc. following an option contract that was scheduled to expire on July 5, 2026.
After this transaction, Andrade directly held 211,100 common shares of Fennec and still held 816,567 stock options with an exercise price of $2.45, according to the filing.
Fennec Pharmaceuticals Inc. reported an insider transaction by its Chief Financial Officer, Robert Andrade. On 01/15/2026, he exercised 10,000 stock options with an exercise price of $2.45 per share, acquiring 10,000 common shares.
Following the transaction, Andrade directly beneficially owned 201,100 common shares and held 826,567 stock options that remained outstanding. The shares were acquired through the exercise of an option contract with a strike price of $2.45 and an expiration date of July 5, 2026.
Fennec Pharmaceuticals chief financial officer Robert Andrade reported exercising stock options and acquiring common shares of the company. On January 7, 2026, he exercised 14,184 stock options at an exercise price of $2.45 per share, which resulted in acquiring 14,184 common shares. After this transaction, he beneficially owned 191,100 common shares directly and held 836,567 stock options directly.
Fennec Pharmaceuticals director reports vested share award
A director of Fennec Pharmaceuticals Inc. reported the acquisition of 5,208 common shares of the company on 12/01/2025. The filing shows these shares were released from restrictions tied to awards originally granted on 3/31/2023 and 5/16/2024, so no purchase price was paid and the transaction is recorded at $0 per share.
Following this vesting event, the director now beneficially owns 87,526 common shares, held directly. The transaction was reported on a Form 4 filed for a single reporting person in the capacity of director of Fennec Pharmaceuticals Inc. (FENC).